Myeloid


The Archer® FusionPlex Myeloid panel is a targeted next-generation sequencing (NGS) test to detect and identify fusions, point mutations and expression levels from 84 genes associated with myeloid-origin malignancies. Using Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment, fusions of all genes in this panel can be identified in a single sequencing test, even without prior knowledge of fusion partners or breakpoints. Additionally, select genes are targeted for molecular barcode-enabled relative expression level detection and point mutation coverage.
Key Features
Efficient, lyophilized workflow

Simultaneously interrogate hundreds of potential gene fusion events and relevant point mutations with under 2 million reads.

Expression profiling

Molecular barcodes enable relative expression level profiling in select genes.

Confirm fusion events

Expression imbalance enabled in select genes for secondary fusion confirmation.

Specifications and Performance

84

Gene Targets

> 10ng

Input Nucleic Acid Required*

> 96%

Unique Molecular On-Target %

2.5 hours

Hands-on Time

9 hours

Total Time

Illumina and
Ion Torrent

Platform

Blood, Fresh Frozen, FFPE

Sample Types

*Input recommendations for FFPE samples vary depending on Archer PreSeq® RNA QC score; 50ng input recommended in absence of PreSeq screening

Gene Targets

LEGEND

SNV/Indel
Expression
Fusion, splicing or exon-skipping

NeeD to Modify Your Panel?

Add any of our wet lab-validated designs to this panel with Archer Assay Designer to build an assay that fits your exact requirements.

  • Find Your Fit

This website stores cookies on your computer. These cookies are used to improve your website and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy.

We won’t track your information when you visit our site. But in order to comply with your preferences, we’ll have to use just one tiny cookie so that you’re not asked to make this choice again.